Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Statin terápia atorvasztatinnal a sebészeti aortabillentyű cserében (STARC)

2026. november 14. frissítette: Lars Peter Riber, Odense University Hospital

Statin terápia atorvasztatinnal a sebészeti aortabillentyű cserében – randomizált, kontrollált vizsgálat

Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery.

The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims are: to examine the ability of a clinically durable Atorvastatin prophylactic regime to prevent the development of POAF and other postoperative complications in these patients.

Patients will be randomized to Atorvastatin 80mg or placebo 7 to 14 days preoperative until 30 days postoperative - a total of 37 to 44 days of treatment.

The medication will be double blinded.

The randomized studie will address the following hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that

1) 7 to 14 days preoperative and until 30 days postoperative treatment with Atorvastatin 80 mg daily reduces the incidence of POAF in statin-naïve patients.

A tanulmány áttekintése

Állapot

Toborzás

Részletes leírás

Trial Participants:

Enrolment for the study is planned to start February 2022 and continue until 266 patients have been enrolled.

DEFINITION OF POAF:

Postoperative AF (I48) is defined as irregular RR-intervals without a traceable p-wave before each QRS complex during at least 30 seconds or entire 12-lead ECG in symptomatic or asymptomatic patients with no prior history of atrial fibrillation or flutter are considered4. Continuous ECG monitoring (8-lead ward monitor) will recognise AF during the entire hospitalization. Anamnesis, electronic health record (EHR), or confirmatory rhythm strip or 12-lead ECG of AF until 30th postoperative day are also considered.

We will also report the burden of atrial fibrillation, and treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.

Course of action:

Patients undergoing elective surgical aortic valve replacement with bioprosthesis at the Department of Cardiac Surgery at Odense University Hospital will be offered participation in the study.

Potentially eligible patients will be screened according to inclusion/exclusion criteria at the time after eligibility of surgery. This is assessed at a multidisciplinary team (MDT) conference (with attendance of cardiologist, cardiac surgeons and anaesthesiologist) based on clinical evaluation, echocardiographic ultrasound, coronary angiography and lung function test.

Patients eligible to participate in the study will be presented with the information of the study at the time of their out-patient appointment, according to normal routine at Odense University Hospital. At this appointment the patient receives a physical examination and journal record is obtained by a cardiac surgeon (approximately 7 to 14 days prior to planned surgery).

The study-information will be given by one of the participating doctors, while the patient has been informed of the possibility of bringing an assessor of their choice. The information will be delivered in a quiet room blocked to other appointments in the Department of Cardiothoracic Surgery.

During this meeting the patient will be informed of the purpose of this study and the written patient information will be submitted in detail. Patients will be given as much time as wanted after the oral information has been delivered to decide if they wish to participate in the study. Patients will be offered the possibility to call one of the doctors taking part in this study during this time, in case of additional questions. Subjects can leave the study at any time for any reason if they wish to do so, without any consequences.

Signed informed consent will be provided prior to any research procedures. A subject is registered when signed informed consent has been provided and assigned a subject identification code by the computer-generated code. A subject is randomized when a treatment and a randomisation number has been provided. A subject is considered enrolled in the study once the subject is randomized.

Patient data from EHR will be conducted according to study endpoints after signed informed consent is provided. Signed consent gives sponsor and sponsors representatives

Randomization:

Allocation to a numbered treatment pack (Atorvastatin or placebo - blinded) Randomization scheme will be set-up by OPEN data manager with control for beta-blockers and age, and then randomization per se will be executed with the use of REDCap.

The following will be recorded at the day of randomization:

  • Conduct information for baseline characteristics
  • Transthoracic Echocardiography measurements

Collect baseline blood sample:

• Troponin, CK-MB, Creatinine, CRP

Commence study medication/treatment

Perioperative interventions and outcomes from the day of surgery to the day of discharge:

  • Duration of aortic cross clamp (ACC), extracorporeal circulation (ECC), ventilatory support, intensive care unit stay period, hospital stay period

  • Continue study medication

  • Blood samples:

    • Preoperative: Troponin, CK-MB, Creatinine, CRP, Plasma-Atorvastatin
    • Serial troponin and CK-MB levels: (6, 24, 48, and 96 hours after surgery).
    • Creatinine levels: 48 and 96 hours after surgery.
    • CRP levels: 48 and 96 hours after surgery
  • Monitor ECG by continuous Holter monitoring to commence as soon as possible after surgery and continue up to post-operative day 5 evening

  • Transthoracic Echocardiography on post-operative day 3-5

  • Record fluid intake and output during the first 48 hours following surgery based on IV fluids administration, blood transfusion (if applicable), oral/nasogastric intake, and urine plus surgical drain output

  • Record intraoperative defibrillation, removal of external pacemaker, new PPM/ICD, vasopressors, blood transfusion, surgical re-exploration, renal replacement therapy, beta-blockers, ACEi/ARB, Amiodarone, Digoxin, Diuretics, Calcium channel blockers, Potassium supplements, NSAIDs or steroids, non-study statin, use of nephrotoxic antibiotics, contrast agents or potassium sparing diuretics (Yes/No)

Assessment at/after discharge from hospital:

  • Continue study medications for 30 days after the surgery
  • Phone call on the 30th postoperative day to evaluate symptoms of discomfort compatible with atrial fibrillation
  • At the end of the study, all excess study medication can be returned at the local drugstore for safe disposal
  • Patient data from EHR will be conducted according to study endpoints.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

266

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányozza a kapcsolattartók biztonsági mentését

Tanulmányi helyek

      • Odense, Dánia, 5000
        • Toborzás
        • Odense University Hospital
        • Kapcsolatba lépni:

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

60 év (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  1. Patients undergoing elective solitary SAVR with bioprosthesis
  2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery
  3. No prior use of HMG-CoA reductase inhibitors the last 3 months and at least 7 days prior to the time of surgery
  4. Age >60 years
  5. Willingness and provision of informed consent to be randomized

Exclusion Criteria:

  1. Prior history of atrial fibrillation
  2. Prior history of cardiac surgery
  3. Known adverse reaction to HMG-CoA reductase inhibitors
  4. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)
  5. Creatinine >200 µmol/L
  6. Known intolerance to statins or history of muscle toxicity with statins
  7. Known intolerance to any of the excipients in Lipistad
  8. Treatment with anti-viral medicine (glecaprevir/pibrentasvir) for hepatitis

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Négyszeres

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Atorvastatin 80 mg

Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Placebo Comparator: Placebo

Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Number of Participants with POAF - In-hospital
Időkeret: In-hospital up to 10 days

In-hospital incidence of POAF assessed by continuous ECG monitoring (8-lead ward monitor).

In-hospital up to 10 days
Number of Participants with POAF - Early
Időkeret: Early (≤30 days) incidence of POAF

Early assessed by anamnesis, electronic health record (EHR), or confirmatory rhythm strip or 12-lead ECG of AF

Early (≤30 days) incidence of POAF
Total duration of POAF - In-hospital
Időkeret: In-hospital up to 10 days

Total duration of POAF episodes experienced in-hospital (unit: hours)

In-hospital up to 10 days

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Rate of All-cause mortality - In-hospital
Időkeret: In hospital up to 10 days

To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes.

Number of deaths in each group.

In hospital up to 10 days
Rate of All-cause mortality - Early
Időkeret: Early (≤30 days)

To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes.

Number of deaths in each group.

Early (≤30 days)
Rate of All-cause mortality - intermediate
Időkeret: intermediate (1 year)

To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes.

Number of deaths in each group.

intermediate (1 year)
Myocardial injury - Tn
Időkeret: After surgery until discharge up to 10 days.

Injury assessed by serial Troponin measurements. Unit:ng/l

After surgery until discharge up to 10 days.
Myocardial injury - CKMB
Időkeret: After surgery until discharge up to 10 days.

Injury assessed by serial CKMB measurements. Unit: μg/l.

After surgery until discharge up to 10 days.
Stroke - Early
Időkeret: Early (≤30 days)

Number of patients with stroke in each group.

Early (≤30 days)
Stroke - Intermediate
Időkeret: Intermediate (1 year)

Number of patients with stroke in each group.

Intermediate (1 year)
Trans ischemic attack - Early
Időkeret: Early (≤30 days)

Number of patients with trans ischemic attack in each group.

Early (≤30 days)
Trans ischemic attack - Intermediate
Időkeret: Intermediate (1 year)

Number of patients with trans ischemic attack in each group.

Intermediate (1 year)
Myocardial infarction - Early
Időkeret: Early (≤30 days)

Number of patients with Myocardial infarction in each group.

Early (≤30 days)
Myocardial infarction - Intermediate
Időkeret: Intermediate (1 year)

Number of patients with Myocardial infarction in each group.

Intermediate (1 year)
Permanent pacemaker - Early
Időkeret: Early (≤30 days)

Number of patients with Permanent pacemaker in each group.

Early (≤30 days)
Permanent pacemaker - Intermediate
Időkeret: Intermediate (1 year)

Number of patients with Permanent pacemaker in each group.

Intermediate (1 year)
ICD implantation - Early
Időkeret: Early (≤30 days)

Number of patients with ICD implantation in each group.

Early (≤30 days)
ICD implantation - Intermediate
Időkeret: Intermediate (1 year)

Number of patients with ICD implantation in each group.

Intermediate (1 year)
Acute kidney injury - Early
Időkeret: Early (≤30 days)

Number of patients with Acute kidney injury in each group.

Early (≤30 days)
Acute kidney injury - Intermediate
Időkeret: Intermediate (1 year)

Number of patients with Acute kidney injury in each group.

Intermediate (1 year)
LVEF
Időkeret: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of LVEF(left ventricular ejection fraction) between groups. Unit: %

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Strain
Időkeret: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of Strain between groups.Unit: %

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Peak gradient
Időkeret: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of peak gradient between groups. Unit: mmHg

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Mean gradient
Időkeret: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of mean gradient between groups. Unit: mmHg

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
TAPSE
Időkeret: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of TAPSE (tricuspid annular plane systolic excursion) between groups. Unit: mm

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Length of stay on ICU
Időkeret: Day of surgery to the day of discharge from ICU. Up to 52 weeks.

Length of stay on ICU after surgery. Unit: Days

Day of surgery to the day of discharge from ICU. Up to 52 weeks.
Length of stay in hospital
Időkeret: Day of surgery to the day of discharge. Up to 52 weeks.

Length of stay in hospital after surgery. Unit: Days

Day of surgery to the day of discharge. Up to 52 weeks.

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Általános kiadványok

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2022. február 1.

Elsődleges befejezés (Becsült)

2027. december 1.

A tanulmány befejezése (Becsült)

2027. december 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2021. augusztus 19.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2021. szeptember 29.

Első közzététel (Tényleges)

2021. október 13.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 18.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 14.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • STARC210421_2

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

Data will be available in anonymized form in accordance with GDPR upon reasonable request.

Rules for external researchers to apply for and access data will be laid out towards the end of the study.

IPD megosztási időkeret

TBA

IPD-megosztási hozzáférési feltételek

TBA

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL
  • NEDV
  • ICF
  • ANALYTIC_CODE
  • CSR

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

az Egyesült Államokban gyártott és onnan exportált termék

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel